N. Baste Rotllan
Hospital Clínic de Barcelona(ES)
Publications by Year
Research Areas
Head and Neck Cancer Studies, Cancer Immunotherapy and Biomarkers, Cancer Diagnosis and Treatment, Thyroid Disorders and Treatments, Lung Cancer Treatments and Mutations
Most-Cited Works
- → KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)(2018)134 cited
- → SEOM clinical guidelines for the treatment of head and neck cancer (2017)(2017)33 cited
- → Association of LIPI score with immune checkpoint inhibitors (ICI) outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (pts)(2018)5 cited
- → Abstract 5001: Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients with resectable squamous cell carcinoma of the head and neck(2019)4 cited
- → Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)(2019)1 cited
- → TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC(2018)1 cited
- → 125P Assessing the accuracy of multiple prognostic scores for immune checkpoint inhibitors (ICI) in patients with advanced solid tumors(2022)1 cited
- → 871P Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study(2024)1 cited
- → Genetic profiling across multiple cancer types using molecular prescreening comprehensive gene panels offered by clinical trials (CT).(2021)1 cited
- → 906P Prognostic impact and therapeutic implications of comprehensive genomic profiling (CGP) in non-metastatic salivary gland cancers (nmSGC)(2024)